The authors of the review article “The complement system in neurodegenerative diseases” (DOI: 10.1042/CS20230513) would like to correct their paper. The authors state that in Table 3 rows 5 and 6, in the “Company” column the words “Annexon” and “Appellis” were inadvertently switched. Additionally, the authors would like to correct an error in the sixth sentence of the “Complement therapeutics in AD” paragraph of their paper. The section “C5aR1-antagonist EP67 reduced amyloid load and synapse loss in 5xFAD mice” should read: “C5aR1-agonist EP67 reduced amyloid load and synapse loss in 5xFAD mice”.

Table 3
Summary of complement drugs used in NDDs including preclinical and clinical studies
DiseaseDrug NameTypeTargetStageCompany
NMO Eculizumab mAb C5 cleavage In clinic 2019 Alexion/AZ 
 Ravulizumab mAb C5 cleavage Approved in EU; awaiting final FDA approval Alexion/AZ 
 Zilucoplan Cyclic peptide C5 cleavage Pre-trial UCB 
ALS Pegcetacoplan Linear peptide C3 cleavage Phase II trial discontinued NCT04579666 Apellis 
 ANX-005 mAb C1q blocker Phase II trial NCT04569435 Annexon 
 Ravulizumab mAb C5 cleavage Phase III failed 2021 NCT04248465 Alexion/AZ 
 Zilucoplan Cyclic peptide C5 cleavage Phase II/III discontinued NCT04436497 UCB 
 CP010 (anti-C6) mAb C6 blocker Preclinical Complement Pharma 
HD ANX-005 mAb C1q blocker Phase II trial NCT04514367 Annexon 
MS None; No tested anti-complement drugs Many tested in models n/a All preclinical n/a 
AD None; No tested anti-complement drugs Some data from models n/a All preclinical n/a 
PD None; No tested anti-complement drugs Minimal model data n/a All preclinical n/a 
SZ None; No tested anti-complement drugs Minimal model data n/a All preclinical n/a 
Tauopathies None; No tested anti-complement drugs Minimal model data n/a All preclinical n/a 
DiseaseDrug NameTypeTargetStageCompany
NMO Eculizumab mAb C5 cleavage In clinic 2019 Alexion/AZ 
 Ravulizumab mAb C5 cleavage Approved in EU; awaiting final FDA approval Alexion/AZ 
 Zilucoplan Cyclic peptide C5 cleavage Pre-trial UCB 
ALS Pegcetacoplan Linear peptide C3 cleavage Phase II trial discontinued NCT04579666 Apellis 
 ANX-005 mAb C1q blocker Phase II trial NCT04569435 Annexon 
 Ravulizumab mAb C5 cleavage Phase III failed 2021 NCT04248465 Alexion/AZ 
 Zilucoplan Cyclic peptide C5 cleavage Phase II/III discontinued NCT04436497 UCB 
 CP010 (anti-C6) mAb C6 blocker Preclinical Complement Pharma 
HD ANX-005 mAb C1q blocker Phase II trial NCT04514367 Annexon 
MS None; No tested anti-complement drugs Many tested in models n/a All preclinical n/a 
AD None; No tested anti-complement drugs Some data from models n/a All preclinical n/a 
PD None; No tested anti-complement drugs Minimal model data n/a All preclinical n/a 
SZ None; No tested anti-complement drugs Minimal model data n/a All preclinical n/a 
Tauopathies None; No tested anti-complement drugs Minimal model data n/a All preclinical n/a 

Abbreviations: mAb, monoclonal antibodies; NMO, Neuromyelitis optica; ALS, Amyotrophic lateral sclerosis; HD, Huntington's disease; MS, multiple sclerosis; HD, Huntington's disease; AD, Alzheimer's disease; PD, Parkinson's disease; Sz, Schizophrenia

The requested correction has been assessed and agreed by the Editorial Board. The authors apologise for this error and declare that this correction does not change the conclusions of the paper. The corrected version of Table 3 is presented here.

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).